Analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report $12.02 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.90 million and the highest estimate coming in at $29.50 million. BioCryst Pharmaceuticals posted sales of $2.73 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 340.3%. The business is scheduled to announce its next earnings report on Monday, March 2nd.
On average, analysts expect that BioCryst Pharmaceuticals will report full-year sales of $21.13 million for the current year, with estimates ranging from $11.00 million to $38.61 million. For the next fiscal year, analysts anticipate that the company will post sales of $39.51 million, with estimates ranging from $10.00 million to $87.47 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.03). BioCryst Pharmaceuticals had a negative net margin of 1,129.38% and a negative return on equity of 2,511.40%. The company had revenue of $1.78 million for the quarter, compared to analysts’ expectations of $4.54 million.
A number of analysts recently weighed in on BCRX shares. Bank of America raised shares of BioCryst Pharmaceuticals from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, October 31st. BidaskClub lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 6th. Finally, ValuEngine raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $8.19.
In other news, insider Megan Sniecinski purchased 45,000 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was acquired at an average cost of $1.45 per share, with a total value of $65,250.00. Following the completion of the transaction, the insider now owns 45,000 shares in the company, valued at approximately $65,250. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jon P. Stonehouse purchased 50,000 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were purchased at an average cost of $1.45 per share, with a total value of $72,500.00. Following the completion of the transaction, the chief executive officer now owns 778,086 shares of the company’s stock, valued at approximately $1,128,224.70. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 120,000 shares of company stock valued at $174,000. Insiders own 5.20% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in BCRX. FMR LLC lifted its position in shares of BioCryst Pharmaceuticals by 15.9% during the first quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock valued at $28,229,000 after buying an additional 475,989 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of BioCryst Pharmaceuticals by 114.8% during the second quarter. Wells Fargo & Company MN now owns 183,419 shares of the biotechnology company’s stock valued at $695,000 after buying an additional 98,038 shares during the last quarter. Bank of Montreal Can lifted its position in shares of BioCryst Pharmaceuticals by 921.9% during the second quarter. Bank of Montreal Can now owns 10,219 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 9,219 shares during the last quarter. Quantamental Technologies LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at about $43,000. Finally, Virtus ETF Advisers LLC lifted its position in shares of BioCryst Pharmaceuticals by 151.6% during the second quarter. Virtus ETF Advisers LLC now owns 78,684 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 47,407 shares during the last quarter. 66.55% of the stock is owned by institutional investors and hedge funds.
NASDAQ:BCRX traded down $0.05 during mid-day trading on Friday, reaching $2.78. The company’s stock had a trading volume of 4,869,218 shares, compared to its average volume of 2,645,843. BioCryst Pharmaceuticals has a 1 year low of $1.38 and a 1 year high of $9.95. The stock has a fifty day moving average of $3.04 and a 200-day moving average of $2.86. The firm has a market capitalization of $419.88 million, a PE ratio of -2.84 and a beta of 2.10.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Further Reading: Are sell-side analysts objective?
Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.